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Background: Aortobifemoral bypass is the standard therapy for complex aortoiliac occlusive disease. The purpose of this
study was to examine the use of endovascular grafts as an alternative to aortobifemoral bypass in patients with advanced
aortoiliac occlusive disease at high risk.
Methods: Endovascular grafts were placed in 23 limbs in 22 patients with TransAtlantic Inter-Society Consensus
document (TASC) type C and D lesions. All procedures were performed in the operating room, and images were obtained
with portable digital fluoroscopy. Surgical exposure of the ipsilateral common femoral artery was performed to enable
safe closure of 9F to 12F sheath sites and to facilitate ipsilateral interventions in the distal external iliac artery.
Concomitant infrainguinal outflow procedures were performed in 6 patients.
Results: Twenty of 22 patients were men; mean patient age was 63.2  3.2 years. Indications for intervention were rest
pain in 12 of 23 limbs and tissue loss in 9 of 22 limbs. Risk factors included hostile abdomen or pelvis in 8 patients,
coronary artery disease in 11 patients, end-stage renal disease in 3 patients, and severe chronic obstructive pulmonary
disease in 3 patients. Each patient received a mean of 1.6 grafts. Initial technical success was 95.2%, with one technical
failure. There was no 30-day mortality. All patients experienced at least one grade improvement per Society for Vascular
Surgery reporting standards. Primary patency at 24 months was 84.2% 8.0%, with a limb salvage rate of 95.3% 5.0%.
Mean ( SD) ankle brachial index improved from 0.49  0.22 to 0.87  0.26 (P < .001).
Conclusion: Endovascular grafting to treat advanced aortoiliac occlusive disease can be accomplished with good clinical
outcome and acceptable short-term patency. This endovascular technique can be a viable alternative to conventional
surgical revascularization in patients with advanced aortoiliac occlusive disease at high risk. (J Vasc Surg 2003;38:
486-91.)
Aortobifemoral bypass is the standard treatment for
aortoiliac occlusive disease, with 5-year patency of approx-
imately 90% to 95%.1-3 However, despite excellent patency
there can be significant morbidity, particularly in elderly
patients and those at high-risk.3 Balloon angioplasty with
stenting has become increasingly popular for treatment of
aortoiliac occlusive disease, but has limitations, with long
segment lesions and occlusions, particularly when involving
the external iliac artery.4,5
Whereas bare stents have limited patency in treatment
of longer segments of aortoiliac occlusive disease, it is
conceivable that covered stents might mimic standard aor-
tobifemoral bypass surgery in that the diseased arterial
segments are “bypassed” through a graft, albeit one in an
endoluminal location. Little is known, however, about the
patency of these endografts in the treatment of aortoiliac
occlusive disease. The purpose of this study was to evaluate
whether use of endovascular grafts to treat complex aor-
toiliac occlusive disease offers a less invasive alternative to
conventional aortobifemoral bypass, with acceptable pa-
tency rate and overall outcome.
METHODS
Medical records were reviewed for 22 consecutive pa-
tients who received endovascular grafts to treat AOID at a
single university medical center between November 2000
and November 2002. In all cases the endovascular graft was
used as primary therapy. Twenty limbs received the Wall-
graft endoprosthesis (Boston Scientific, Natick, Mass), and
2 limbs received the Viabahn endoprosthesis (W. L. Gore
& Associates, Flagstaff, Ariz). Patients with significant co-
morbid conditions who were considered at high risk for
aortobifemoral bypass were considered for endografts (Ta-
ble I). Risk factors included hostile abdomen in 8 patients;
the remaining patients were considered medically at high
risk for aortobifemoral bypass. The severity and duration of
aortoiliac occlusive disease were categorized according to
the Trans-Atlantic Intersociety Consensus (TASC) classifi-
cation,6 and demonstrated diffuse aortoiliac occlusive dis-
ease (TASC C and D patterns; Table II). The angiographic
run-off score was determined from preoperative arterio-
grams according to the Ad Hoc Committee on Reporting
Standards of the Society for Vascular Surgery/Interna-
tional Society for Cardiovascular Surgery.7 Periprocedural
antithrombotic therapy consisted of aspirin at a dose of 81
to 325 mg.
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Surgical technique. All endografts were placed in the
operating room, with open technique, with the patient
under general anesthesia. Once the ipsilateral artery was
exposed, proximal and distal control was obtained with
Rumel tourniquets before arteriotomy. Initially, access was
secured with a 6F short sheath. The diseased segments of
aortoiliac occlusive disease were traversed with a 0.035
hydrophilic guide wire under fluoroscopic guidance (OEC
9800; General Electric Medical Systems, Milwaukee, Wis).
Once access across the lesion was obtained, a 0.035 Bent-
son wire was inserted. Next a larger sheath (9F-12F) was
placed, and an aortic flush-type catheter was placed in the
aorta for preliminary imaging. Marker catheters were not
routinely used, but were used selectively to assist in selec-
tion of endograft length. Systemic anticoagulation with
heparin (100 U/kg) was carried out, and was reversed with
protamine sulfate at completion. All occluded and stenotic
segments were dilated at balloon angioplasty to a diameter
of 7 to 12 mm with standard technique. This was followed
by deployment of the endograft. Final balloon dilation to 7
to 12 mm was performed, depending on the diameter of
the endograft selected (Figs 1 to 4). In two patients the the
segment at the internal iliac artery orifice was treated with a
bare stent. Whenever possible, the ipsilateral internal iliac
artery was preserved. Technical success was determined if
residual stenosis was less than 30% at angiography or there
was no hemodynamic pressure gradient across the lesion.
Pressure measurements were used selectively when the
angiogram showed residual stenosis of uncertain hemody-
namic significance. Completion angiography was per-
formed in all procedures with a flush catheter positioned in
the distal aorta. The artery was closed primarily if an out-
flow procedure was not performed.
Postoperative follow-up. Postoperatively, patency
was determined if there was an ipsilateral palpable femoral
pulse, and ankle brachial index (ABI) and toe pressure were
monitored with serial measurements. Patients were seen at
3-month intervals in the first year, then every 6 months.
Clinical improvement was assessed with standardized Soci-
ety for Vascular Surgery reporting standards.7
Statistical analysis. Continuous variables such as pre-
operative and postoperative ABI and toe pressure were
analyzed with unpaired t test. Graft patency and limb
salvage were determined with Kaplan-Meier survival
curves. Statistical analysis was performed with SPSS for
Windows, version 10.0 (SPSS Inc, Chicago, Ill). P  .05
was considered significant. Values are reported as mean 
SD.
RESULTS
Twenty-three limbs were treated in 22 patients (20
men, 2 women). Mean patient age was 63.4  8.9 years.
Technical success was achieved in 22 of 23 limbs (95.2%).
On average, 1.6  0.7 grafts (8.4  1.2 mm) were de-
ployed per patient. Balloon angioplasty after graft deploy-
ment was performed in each case, with 8.1  1.1 mm
balloon catheters.
Indications for surgery included ischemic rest pain or
tissue loss in most patients (Table II). Mean preoperative
femoral run-off score was 3.2  2.1 (range, 1-7). Eight
limbs had occlusions of entire segments of the external iliac
artery or the common iliac artery, classified as TASC D
(Figs 1-4). Thirteen limbs were categorized as having
TASC C disease. Two patients underwent concomitant
endovascular stent grafting to treat abdominal aortic aneu-
rysm and coexisting aortoiliac occlusive disease. Adjunctive
outflow procedures were performed in the ipsilateral limb
in 7 patients: profundaplasty in 3 patients, common femo-
ral patch angioplasty in 2 patients, femorofemoral bypass
grafting in 1 patient, and femoropopliteal bypass grafting in
1 patient. To treat external iliac artery lesions, ipsilateral
common iliac artery angioplasty or stenting was performed
in 6 patients, and contralateral angioplasty or stenting was
performed in 5 patients. Bilateral endografts were placed in
1 patient.
Cumulative primary patency at 24 months was 84.4%
8.4% (Fig 5). Limb salvage at 24 months was 95.3%4.0%
(Fig 6; Table III). Mean follow-up was 12.4 months.
Postoperative ABI improved significantly over preoperative
values (0.87 0.26 vs 0.47 0.22; P .001). According
to SVS reporting standards, clinical status improved in all
patients (mean improvement, 2.45  0.76).
Graft occlusion. One failure occurred, due to inabil-
ity to maintain patency of the endograft during the opera-
tive procedure. This was noted at once, and was resolved
with femorofemoral bypass grafting performed at the same
Table II. Definitions of TASC C and D iliac lesions
TASC type C iliac lesions
Bilateral 5–10 cm long stenosis of CIA or EIA, not extending
into CFA
Unilateral EIA occlusion not extending into CFA
Unilateral EIA stenosis extending into CFA
Bilateral CIA occlusion
TASC type D iliac lesions
Diffuse, multiple unilateral stenoses involving CIA, EIA, and
CFA (usually 10 cm)
Unilateral occlusion involving both CIA and EIA
Bilateral EIA occlusions
Diffuse disease involving aorta and both iliac arteries
Iliac stenoses in patient with abdominal aortic aneurysm or other
lesion requiring aortic or iliac surgery
CIA, Common iliac artery; EIA, external iliac artery; CFA, common femoral
artery.
Table I. Comorbid conditions
Condition
Patients (N  22)
n %
Hypertension 22 100
Tobacco use 19 86
Hyperlipidemia 9 41
Hostile abdomen 8 36
Coronary artery disease 9 41
Diabetes 7 31
End-stage renal disease 3 13.3
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setting. In this case, the external iliac artery was occluded
and of small caliber (approximately 6 mm diameter). Inabil-
ity to dilate the endograft beyond 6 mm may have contrib-
uted to this technical failure. Another graft failed 44 days
after insertion in the external iliac artery, likely because of
poor femoral runoff that was not adequately addressed at
the original procedure. This failure ultimately resulted in
limb loss. The third failure occurred 10 months after de-
ployment, originally performed to treat concomitant severe
external iliac artery occlusive disease in a patient undergo-
ing stent-graft repair of an abdominal aortic aneurysm. The
stent-graft limb of the aortic device maintained patency via
the ipsilateral internal iliac artery, however, and no signifi-
cant ischemia occurred as a result of the occlusion.
DISCUSSION
Extensive aortoiliac occlusive disease in patients at high
risk who cannot undergo standard aortobifemoral bypass
has often been revascularized with extra-anatomic bypass
grafting, such as axillobifemoral grafting. The disadvan-
tages of the extra-anatomic approach include risk for com-
plications to the donor limb, graft infection, and relatively
low patency rate, particularly in patients with impaired
femoral runoff.8,9 An in-line alternative, such as endovas-
cular grafting, is therefore attractive, because it averts some
of the limitations of an axillofemoral graft and can be
performed through a groin incision. Use of such grafts has
Fig 1. A 9F to 12F sheath was placed, and an aortic flush-type
catheter was inserted into the aorta for preliminary imaging.
Fig 2. A 9F to 12F sheath was placed, and an aortic flush-type
catheter was inserted into the aorta for preliminary imaging.
Fig 3. Occluded and stenotic segments were dilated with balloon
angioplasty to a diameter of 7 to 12 mm, with standard technique,
followed by deployment of the endograft.
Fig 4. Occluded and stenotic segments were dilated with balloon
angioplasty to a diameter of 7 to 12 mm, with standard technique,
followed by deployment of the endograft.
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been reported in the literature, most notably by Marin and
colleagues from Montefiore Medical Center.10-12 Their
experience has demonstrated that use of endografts in
patients with aortoiliac occlusive disease who are at high
risk is associated with good clinical results, with 4-year
primary patency rate of 66% and limb salvage rate of 89%.12
Perhaps the most significant differences between the
our technique and theirs involve the newer endograft de-
vices now available. In the Montefiore experience, predi-
lated polytetrafluoroethylene grafts were hand-sewn to
balloon-expandable stents, then delivered into the com-
mon iliac artery with relatively large sheaths (14F). This
technique can also require use of a second angioplasty
balloon, or “tip balloon,” which serves the purpose of a
dilator tip for the large sheath.12 Another potential disad-
vantage of this endograft device is that the graft completely
relines the treated iliac arteries and therefore would cover
and occlude a patent internal iliac artery if deployed from
the common iliac artery or aorta. Furthermore, the graft
must be extracted from the arteriotomy, trimmed, and then
sewn to the common femoral artery.
With the relatively recent (late 2000) approval by the
Food and Drug Administration (FDA) of commercially
manufactured covered stents, such as the Wallgraft endo-
prosthesis (Boston Scientific) and the Viabahn endopros-
thesis (W. L. Gore), the aortobifemoral bypass endograft-
ing procedure is greatly simplified. These devices are
inserted through smaller sheaths (9F-12F) with diameter
(7-14 mm) suitable for iliac artery deployment. It should be
noted that FDA approval for these devices is for biliary and
tracheobronchial deployment only. The variety of available
device lengths and diameters allows appropriate device
selection for a wide range of iliac deployment situations.
The Viabahn and Wallgraft devices are both suitable for
use in complex aortoiliac occlusive disease, but characteris-
tics of each device bear discussion. We have more experi-
ence with the Wallgraft device, because it was the first one
approved by the FDA. A key advantage of the Wallgraft
device is that, like the Wallstent, it can be reconstrained
within the delivery sheath if the operator wishes to alter the
location of delivery or remove the device altogether. Un-
fortunately, the mechanical properties that enable recon-
strainability require considerable elongation of the device
within its delivery sheath. This becomes a problem during
deployment if the treated artery has not been adequately
predilated, because the Wallgraft tends to remain con-
strained and does not fully expand even after balloon cath-
eter dilation. It is therefore imperative that adequate predi-
lation be performed before deploying the Wallgraft. The
Viabahn device also must be placed after adequate predila-
tion, but for a slightly different reason. The Viabahn graft is
wrapped on itself within the delivery system, and will not
fully deploy if it is placed in a stenotic artery that has not
been adequately predilated. An advantage of the Viabahn
device is that it is not elongated within its delivery system,
so there is no foreshortening on deployment, which makes
accurate length positioning of the endograft more straight-
forward.
Although it may be possible to deploy these devices via
a percutaneous approach, we have found several advantages
to an open surgical approach. First, the open approach
enables safe and secure closure of the arteriotomy. While it
may be possible to achieve hemostasis with one of the many
closure devices, such devices carry increased risk and in











0 23 3 1 95.2  4.0
3 19 1 0 95.2  4.0
6 18 3 0 95.2  4.0
9 15 3 0 95.2  4.0
12 12 2 0 95.2  4.0
15 10 1 0 95.2  4.0
18 6 3 0 95.2  4.0
21 3 1 0 95.2  4.0
24 2 2 0 95.2  4.0
*Values represent mean  SE.
Fig 5. Cumulative primary patency at 24 months (84.4% 8.4%,
mean  SD).
Fig 6. Limb salvage rate at 24 months (95.3%  4.0%, mean 
SD).
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many cases are contraindicated in the presence of common
femoral artery occlusive disease, which is highly prevalent in
these patients, particularly those with extensive external
iliac occlusive disease. Furthermore, suture-based closure
devices are approved for use only up to 10F. Second, many
of these patients require concomitant infrainguinal surgical
revascularization originating from the common femoral
artery. Other patients have coexisting common femoral and
profunda occlusive disease that can be treated with endar-
terectomy when using the open approach. Third, for those
patients with severe external iliac disease that extends to the
inguinal ligament, the arteriotomy can be performed in the
proximal superficial femoral artery if an open approach is
used, enabling an ipsilateral approach to endograft deploy-
ment. Access through the ipsilateral superficial femoral
artery enables additional “working room” for the intro-
ducer sheath when treating distal iliac lesions. Although it is
possible, and in some cases even necessary, to use a con-
tralateral “up and over” approach for crossing the lesion
with extensive external iliac artery disease, the ipsilateral
approach greatly facilitates positioning of these moderately
large-caliber sheaths and devices. When a contralateral fem-
oral access is needed to cross an external iliac occlusion, we
extract the wire from the ipsilateral common femoral artery,
and re-cross retrograde and exchange for another working
wire for ipsilateral deployment. This is particularly helpful
in proximal common iliac occlusive disease that requires
endografting.
There are a few additional advantages to the open
approach. The femoral artery can be flushed of atheroscle-
rotic debris that can be dislodged when predilating exten-
sive occluded iliac segments. We have found this necessary
in some cases, to prevent distal embolization. Occasionally
the occluded iliac artery segments cannot be crossed with a
guide wire, particularly with long segment occlusions that
are densely calcified or if excessive tortuosity is present. In
such cases the use of an open surgical approach permits
immediate conversion to conventional surgical revascular-
ization. Finally, and perhaps the most controversial “advan-
tage” for surgeons, the open approach facilitates gaining
experience with advanced endovascular techniques in cen-
ters in which access to an imaging suite is limited. However,
we do not believe this constitutes adequate justification for
the preferential use of portable fluoroscopy in the operating
room to image focal iliac lesions that are best treated in a
dedicated imaging suite with standard percutaneous tech-
niques.
Our study has many limitations, and there are unan-
swered questions. Perhaps the most significant issue is
whether a covered stent performs better than a bare stent,
even in diffuse, long segment aortoiliac occlusive disease. A
recently reported, but as yet unpublished, clinical trial
comparing endografts with bare stents (Wallgraft and Wall-
stent; Boston Scientific) for treating complex iliac occlusive
lesions showed superior patency with the endograft versus
the stent alone (100% vs 92.5% primary patency at 1 year;
P  .037).13 However, since these results have yet to be
published or validated by others, it cannot be concluded
that endografts are necessarily superior to stents alone. It is
possible that one reason that stenting alone in complex
external iliac artery occlusive disease often fails to achieve
good long-term patency is that concomitant occlusive dis-
ease in the runoff common femoral and profunda femoral
arteries cannot be easily dealt with using percutaneous
procedures. Indeed, Nelson et al,14 from Dartmouth, re-
cently demonstrated 97% assisted primary patency at 1 year
with a technique that combines use of a standard, self-
expanding stent in the external iliac artery with common
femoral endarterectomy. It is certainly possible that the
83% 2-year primary patency rate in our study can be attrib-
uted more to improving the femoral runoff in 6 patients
than to the choice of endograft over bare stent to treat the
iliac lesions.
Another disadvantage of endografts compared with
stents is cost. The endografts used in this study cost about
twice as much as a standard stent. Furthermore, stents are
routinely deployed with 6F sheaths and percutaneous tech-
nique, which results in considerable cost savings compared
with use of an operating room for the open endograft
technique.
In some situations use of an endograft, as described,
would likely not be successful and would be contraindi-
cated. Such situations would include juxtarenal aortic oc-
clusion, small-caliber external iliac arteries that cannot be
dilated to more than 6 mm, and extensive occlusions that
cannot be traversed with a guide wire from either the
ipsilateral or contralateral femoral approach.
We emphasize that our use of these endografts to treat
complex aortoiliac occlusive disease has generally been
limited to patients with a hostile abdomen or who are
medically unfit for aortobifemoral bypass. In patients at low
risk with extensive aortoiliac occlusive disease we continue
to recommend aortobifemoral bypass as the most durable
approach to revascularization. At best, our results indicate
that endografts can be used with reasonably good short-
term results in patients considered at high risk for conven-
tional aortobifemoral bypass surgery. Extended follow-up
with longer term results and larger numbers of patients will
be needed before we can conclude that this technique offers
comparable outcome to other less invasive revasculariza-
tion procedures, such as axillofemoral bypass grafting.
Should continued study indicate favorable results, prospec-
tive trials to evaluate endografts and stents alone compared
with other methods of revascularization will be needed to
assess the proper role of these endovascular techniques for
treatment of complex aortoiliac occlusive disease.
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